Atara Therapeutics’ Ebvallo, already marketed in Europe for a transplant-related blood cancer, will not hit the U.S. market ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...

Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

In this episode of Denatured, BioSpace's Head of Insights Lori Ellis talks to Dr. Peter Marks, Director, CBER, about his thoughts on the future of cell and gene therapies.

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to ...

An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, ...

Lykos Therapeutics is currently working out ways to fund an additional Phase III study for its MDMA-assisted PTSD therapy ...